Wei’s findings suggest that heightened GGT5 levels in cancer-associated fibroblasts (CAFs) contribute to cancer cell survival and drug resistance, indicating GGT5’s potential as a therapeutic target in lung adenocarcinoma [13]. This evidence concerns the gene GGT5 and lung adenocarcinoma.